



Advaxis Appoints Molly Henderson as Chief Financial Officer

June 6, 2018

PRINCETON, N.J.--(BUSINESS WIRE)--[Advaxis, Inc.](#) (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial Officer, effective June 6, 2018.

Ms. Henderson joins Advaxis from Cedar Cliff, LLC, where she served as a financial and business consultant to high-growth entrepreneurial companies. Previously she was Chief Financial Officer at Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) (Nasdaq: IOVA), an immuno-oncology company where she was responsible for all financial, SEC reporting, legal, governance, human resources and IT-related functions, and raised \$100 million in equity capital. In her over twenty years of financial experience, Ms. Henderson brings to Advaxis a demonstrated set of skills that includes operational efficiency, fund raising, M&A evaluation, investor relations, accounting and financial controls.

"We welcome Molly to the Advaxis team and look forward to her contributions," said Ken Berlin, President and Chief Executive Officer. "Molly has significant experience as a public company CFO in the healthcare industry, including immuno-oncology, and in managing the capital efficiency and financial requirements of a development-stage biotechnology company like Advaxis. We are very pleased to add Molly to our executive management team."

Commenting on her appointment, Ms. Henderson said, "I have spent the majority of my professional career supporting the development of exciting growth companies in the healthcare industry, including managing the finance function, raising capital and creating an infrastructure for success. In particular, given my recent experience in cancer immunotherapy, I am excited to be joining Advaxis and to support its promising *Lm* platform technology."

Prior to Iovance, for more than a decade Ms. Henderson was Chief Business & Financial Officer, Senior Vice President of VirtualScopics, Inc. (formerly Nasdaq: VSCP) during a period when the company evolved from an early stage company to a publicly-traded profitable business serving the biotechnology and pharmaceutical industries. Earlier in her career Ms. Henderson was Corporate Controller at Ultralife Corporation and an expert advisor to entrepreneurs in Switzerland. She began her career as an audit manager at PricewaterhouseCoopers.

Ms. Henderson holds an MBA and a BS in Accounting from the University at Buffalo. She is a licensed CPA (inactive) in the State of New York.

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary *Lm*-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated *Listeria monocytogenes* (*Lm*) bioengineered to secrete antigen/adjuvant fusion proteins. These *Lm*-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot/ cancer antigens and prostate cancer.

To learn more about Advaxis, visit www.advaxis.com and connect on [Twitter](#), [LinkedIn](#), [Facebook](#), and [YouTube](#).

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis' ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis' proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis' SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, and on Form 10-Q for the quarter ended January 31, 2018, which are available at www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACT:

Company:
[Advaxis, Inc.](#)
Noelle Heber, 609-250-7575

"Molly has significant experience as a public company CFO in the healthcare industry, including immuno-oncology, and in managing the capital efficiency and financial requirements of a development-stage biotechnology company like Advaxis. We are very pleased to add Molly to our executive management team."

Sr. Director Corporate Communications and Government Affairs

Heber@advaxis.com

or

[Advaxis, Inc.](#)

Ranya Dajani, 609-250-7559

Vice President, Business Development

Dajani@advaxis.com

or

Investors:

[LHA Investor Relations](#)

Miriam Weber Miller, 212-838-3777

Mmiller@lhai.com